Merck KGaA’s Rare Tumor Strategy Takes Shape With $3.9B SpringWorks Acquisition
Frank Vinluan , 2025-04-28 17:28:00 Merck KGaA is building up its portfolio and pipeline with a $3.9 billion deal to acquire SpringWorks Therapeutics, a company with two FDA-approved rare tumor drugs, both of which offer the potential to expand their uses to the treatment of several types of cancer. According to financial terms announced Monday,…